Efficacy and Safety Over 2 Years of Exenatide Plus Dapagliflozin in the DURATION-8 Study: A Multicenter, Double-Blind, Phase 3, Randomized Controlled Trial.
Serge A JabbourJuan Pablo FriasAzazuddin AhmedElise HardyJasmine ChoiC David SjöströmCristian GujaPublished in: Diabetes care (2020)
In this exploratory analysis, among those individuals who completed the trial without rescue therapy, there was clinically relevant efficacy over 2 years with exenatide QW plus dapagliflozin, with no unexpected safety findings.